Met Non Small Cell Cancer Registry (MOMENT)
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorEMD Serono Research & Development Institute, Inc.
About this trial
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants who signed ICF
Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
Participants who are starting or are already being treated with systemic therapy
Disqualifiers
Participants who are enrolled in a clinical trial
Trial population
Participants with advanced stage (stages IIIB-IV) NSCLC and confirmed METex14 skipping alterations who are initiating or already treated with a systemic therapy will be included.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
700 Participants
are grouped into 1 trial groupGroup A: Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
Trial outcomes
Primary outcomes
1
Best Overall Response (BOR)
Time frame
Through study completion, up to approximately 4.9 years2
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Time frame
Up to approximately 4.9 years3
Overall Survival (OS)
Time frame
Through study completion, up to approximately 4.9 years4
Number of Participants with Adverse Events (AEs)
Time frame
Up to approximately 4.9 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
EMD Serono Research & Development Institute, Inc.
Lead sponsor
Merck KGaA, Darmstadt, Germany
Collaborator
Source ClinicalTrials.gov